ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
about
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerInhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsEGFR/HER-targeted therapeutics in ovarian cancerHER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cellsCranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum-resistant ovarian cancer cells to paraplatin.Analysis of inhibitor of apoptosis protein family expression during mammary gland development.Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway.Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapyA phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation.ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.Advances in molecular therapies in patients with brain tumors.RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.Developing inhibitors of the epidermal growth factor receptor for cancer treatment.The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.Therapeutic potential of tyrosine kinase inhibitors in breast cancer.Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancerEpidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cellsA novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA, and activated PAMAM dendrimers.Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration.Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patientsFGFR2 signaling underlies p63 oncogenic function in squamous cell carcinomaAnti-epidermal growth factor receptor strategies for advanced breast cancer.Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.The P2RY2 Receptor Induces Carcinoma Cell Migration and EMT Through Cross-Talk With Epidermal Growth Factor Receptor.Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells.DRR regulates AKT activation to drive brain cancer invasion.A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer.Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.Human secreted proteins SLURP-1 and SLURP-2 control the growth of epithelial cancer cells via interactions with nicotinic acetylcholine receptors.Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
P2860
Q24633878-E52EA50D-0D17-4C8B-AD8E-2F7AF40FB87EQ24795614-9424C5DD-7A4B-413B-9505-AA5E46273E5AQ24810622-16FC57D3-271E-4994-8057-BE1179E4500FQ26863231-CE04B830-88E2-4A20-9F0F-CFBB47788AACQ28473274-C399051A-782C-49EC-89DF-32F6E9FF74DAQ33403233-D7423841-4468-4670-9D3D-7ECB171DDC09Q33618500-0334FBC0-479D-4F15-9D03-8C341ECD72F3Q33665092-083E7913-F994-4DE7-BF33-AB7D378EF511Q34023653-E8B381CD-1AD7-4E35-8394-97D608EC2F3DQ34077853-78E1889E-D175-4406-8C8F-434BDEEFD0DAQ34297943-02BD2043-4B62-487E-9979-C2017DE40DF1Q34582111-1279B85D-FA6C-4422-8D6D-669208A77080Q35063410-9FEE8D5E-5A6B-4BB0-B1DF-6351313F7657Q35113656-2478B941-4C5C-4B42-9F01-891EE619231CQ35124840-01685579-B460-4F67-8C96-D4859D1F6D2EQ35157038-C091C98D-29C8-4787-9202-FB1FCF98EF79Q35247181-61DFA326-374E-44F7-845E-4824BF61AA61Q35589209-EC1B8455-3986-499C-89CE-2C1EBE27F1DEQ35625440-8CCFF66C-0FE9-4FF8-9E68-15FCB07666D9Q36083065-51368080-A56D-4130-895A-40D812806944Q36090650-13303D26-05DB-4E1D-A5AE-18298989C7AAQ36191332-24C09896-EA6A-4B94-81D8-FE5FAD963F08Q36321148-6A8C45FE-C2AF-442D-97B7-0497EACD5868Q36626059-A1635023-27BE-4D7E-BD75-AA538155B9D3Q37038658-20F0D8D0-3850-4161-BC24-ED7918EE030DQ37052955-4D2BE983-8800-4B12-B2BD-85F6A15E4B78Q37293327-B3A5555C-45F8-4579-B621-546391A7F5DFQ37582080-D1132593-BC06-488A-87DB-4F48EA98B0D8Q37863629-7C715DFF-06EA-4F78-8D1C-175FB65C72A4Q38798293-FCDBE8B4-8855-4C88-B74A-0525C9719435Q38829837-9BE0A315-5594-4916-B957-5D44997BEF4EQ39392579-6285153C-D4D3-4E11-9E2A-B6F9C73A8B5AQ39890068-E8EC8F03-5780-48BC-9A27-F70989AB4A09Q40543731-C39E0C73-0512-417C-A6D5-2C4D0A5FD0C2Q45412782-1ED3FE46-9C10-4F0D-8A83-022C53F40C5CQ45949842-0508E6EC-0FA9-4008-9B1E-7385262519C8Q46601914-122E5BCC-3FA5-45A4-8A69-3FB31A347519Q47134459-DC0FAC9E-3751-45A9-ACF5-436811FEEE01Q52673918-A7FE7E40-0F8C-437A-ABF9-FD1CC36992F3Q54632156-C1577D57-D999-4302-94B9-84D3FC321861
P2860
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@ast
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@en
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@nl
type
label
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@ast
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@en
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@nl
prefLabel
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@ast
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@en
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@nl
P2093
P2860
P356
P1476
ZD1839 (Iressa), a novel epide ...... without erbB2 overexpression.
@en
P2093
P2860
P304
P356
10.1002/IJC.1557
P577
2001-12-01T00:00:00Z